Dr. Alejandro Pedrozo III, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 422
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
FL license ME81430
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 422
- Services billed
- 2,536
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,322 | 147 |
| Established patient office or other outpatient visit, 20-29 minutes | 563 | 284 |
| Destruction of precancer skin growth, 1 growth | 267 | 161 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | 132 | 59 |
| New patient office or other outpatient visit, 30-44 minutes | 123 | 123 |
| Established patient office or other outpatient visit, 10-19 minutes | 121 | 88 |
| Biopsy of related skin growth, first growth | 111 | 101 |
| Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | 73 | 71 |
| Destruction of skin growth, 1-14 growths | 52 | 41 |
| Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | 45 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 29 payments worth $719 in total to this clinician.
| Incyte Corporation | $346 |
|---|---|
| Novartis Pharmaceuticals Corporation | $223 |
| Pfizer Inc. | $61.06 |
| Galderma Laboratories, L.P. | $49.59 |
| UCB, Inc. | $38.55 |
| Food and Beverage | $719 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $10,000 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
Sanofi US Services Inc. · Completed · NCT06687967
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.